Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Microarray Innovations in LEukemia (MILE) study: Stage 1 data

ABSTRACT: An International Multi-Center Study to Define the Clinical Utility of Microarray–Based Gene Expression Profiling in the Diagnosis and Sub-classification of Leukemia (MILE Study) Established in 2005, the MILE (Microarray Innovations in LEukemia) study research program included 11 participating centers in three continents. This cohort of n=2,096 samples represents data on the retrospective whole-genome analysis phase. This dataset is part of the MILE Study (Microarray Innovations In LEukemia) program, headed by the European Leukemia Network (ELN) and sponsored by Roche Molecular Systems, Inc.

ORGANISM(S): Homo sapiens

PROVIDER: GSE13159 | GEO | 2009/09/30

SECONDARY ACCESSION(S): PRJNA114111

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Microarray Innovations in LEukemia (MILE) study: Stage 2 data

Project description:An International Multi-Center Study to Define the Clinical Utility of Microarray–Based Gene Expression Profiling in the Diagnosis and Sub-classification of Leukemia (MILE Study) Established in 2005, the MILE (Microarray Innovations in LEukemia) study research program included 11 participating centers in three continents. This cohort of n=1,152 samples represents data on the retrospective whole-genome analysis phase. This dataset is part of the MILE Study (Microarray Innovations In LEukemia) program, headed by the European Leukemia Network (ELN) and sponsored by Roche Molecular Systems, Inc.

2009-09-30 | GSE13164 | GEO

Microarray Innovations in LEukemia (MILE) study: Stage 2 data

Project description:An International Multi-Center Study to Define the Clinical Utility of MicroarrayâBased Gene Expression Profiling in the Diagnosis and Sub-classification of Leukemia (MILE Study) Established in 2005, the MILE (Microarray Innovations in LEukemia) study research program included 11 participating centers in three continents. This cohort of n=1,152 samples represents data on the retrospective whole-genome analysis phase. This dataset is part of the MILE Study (Microarray Innovations In LEukemia) program, headed by the European Leukemia Network (ELN) and sponsored by Roche Molecular Systems, Inc. 1,152 blood or bone marrow samples of acute and chronic leukemia patients were hybridized to the Roche AmpliChip Leukemia Custom Microarray

2010-05-23 | E-GEOD-13164 | biostudies-arrayexpress

Microarray Innovations in LEukemia (MILE) study: Stage 1 data

Project description:An International Multi-Center Study to Define the Clinical Utility of Microarray–Based Gene Expression Profiling in the Diagnosis and Sub-classification of Leukemia (MILE Study) Established in 2005, the MILE (Microarray Innovations in LEukemia) study research program included 11 participating centers in three continents. This cohort of n=2,096 samples represents data on the retrospective whole-genome analysis phase. This dataset is part of the MILE Study (Microarray Innovations In LEukemia) program, headed by the European Leukemia Network (ELN) and sponsored by Roche Molecular Systems, Inc. 2096 blood or bone marrow samples of acute and chronic leukemia patients were hybridized to Affymetrix HG-U133 Plus 2.0 GeneChips.

2009-09-30 | E-GEOD-13159 | biostudies-arrayexpress

Transcription profiling of human samples from the MILE (Microarray Innovations In LEukemia) study pre-phase to investigate cross site reproducibility

Project description:An international standardization program towards the application of gene expression profiling in routine leukaemia diagnostics: The MILE study pre-phase. A total of 11 laboratories from three continents performed 204 analyses using a whole-genome expression microarray. In an effort to standardize the microarray procedure, each participating centre was equipped with identical hardware, software, and reagents. Designated study operators received intensive individual training on the sample preparation protocol. Experiment Overall Design: This study is part of the MILE Study (Microarray Innovations In LEukemia) program, headed by the European Leukaemia Network (ELN) and sponsored by Roche Molecular Systems, Inc. Experiment Overall Design: Each laboratory prepared two separate cell line total RNA samples, as well as three replicate leukaemia patient lysates in two distinct project stages: (i) a five-day course of protocol training, and (ii) independent proficiency testing. Experiment Overall Design: Using unsupervised, supervised, and rÂ² correlation analyses we demonstrated that microarray analysis can be performed not only with remarkably high intra-laboratory reproducibility but also with comparable quality and reliability between eleven distinct laboratories.

2008-10-21 | E-GEOD-11135 | biostudies-arrayexpress

Transcription profiling of human 164 MDS, 202 AML and 69 non-leukemia bone marrow samples to develop a gene array prediction of AML transformation in MDSm subset of MILE study data

Project description:Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome (MDS); An array-based Diagnostic Classifier (DC) model, developed for and evaluated during the MILE study, correctly identified ~50% of the unfractionated MDS specimens submitted to the study; predictions for the other samples were split between “none-of-the-targets” classes and AML signatures, but this distinction also reflected clinical outcome in terms of time to AML transformation. Furthermore, an improved Prognostic Classifier (PC) model was developed that correlated with both time to AML transformation and overall survival. Experiment Overall Design: 164 MDS, 202 AML and 69 non-leukemia bone marrow samples were hybridized to Affymetrix HG-U133 Plus 2.0 GeneChips. Experiment Overall Design: This dataset is a subset of the MILE Study (Microarray Innovations In LEukemia) program, headed by the European Leukemia Network (ELN) and sponsored by Roche Molecular Systems, Inc.

2009-06-22 | E-GEOD-15061 | biostudies-arrayexpress